# OnCo record duo-o (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/duo-o/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "duo-o", "NCT03737643" ;
  schema:name "DUO-O / ENGOT-ov46"@en ;
  schema:description "Adding immunotherapy and olaparib to bevacizumab slowed progression but has not improved survival, and the regimen is not approved."@en ;
  schema:url <https://onco.cc/trials/duo-o/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03737643>, <https://www.onclive.com/view/chemotherapy-plus-durvalumab-bevacizumab-and-olaparib-fails-to-offer-os-benefit-in-newly-diagnosed-non-tbrca-mutated-ovarian-cancer> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  schema:startDate "2019-01-04" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .